tirzepatide dysesthesia In four recent placebo-controlled clinical trials, dysesthesia, an unpleasant sensation that's perceived on or under the skin, was reported as a side effect of the GLP-1 agonist semaglutide in 5-23% of recipients Achieve Weight Loss with Tirzepatide
Description
If you enjoy an occasional can, thats okay

Treatment discontinuation (34%) was the most common censoring reason (Supplementary Table 20)

2024;167(2):402404.e3

10.2337/db23-127-OR 77.Wilson JM, Nikooienejad A, Robins DA, et al

A gradual dose escalation is the primary strategy used to improve tolerability and ensure you can continue with the therapy
